Hemolysis and Iron Metabolism in the Context of IMPELLA Management

Background and Purpose Hemolysis is a common and significant complication associated with Impella implantation, primarily attributed to shear stress. This retrospective study investigates the potential relationship between iron metabolism and hemolysis in patients with Impella devices to better understand the underlying mechanisms of this complication. Materials and Methods This study analyzed patients who underwent Impella implantation between 2018 and 2023. Iron metabolism and hemolysis were assessed using transferrin saturation (TSAT) and serum transferrin levels. Multivariate analysis was adjusted for body surface area, pulmonary artery pulsatility index, an aortic and mitral annulus angle of less than 125 degrees, left ventricular end-diastolic dimension, and maintenance pump level. Results Sixty-one patients with a mean age of 68 ± 11.8 years were included. Among these patients, 55.7% had a TSAT greater than 20%, with 20.7% in the hemolysis group and 87.5% in the non-hemolysis group. Average transferrin levels were 195 mg/dL (range: 173–249 mg/dL), with higher levels observed in the hemolysis group (245 mg/dL; 218–267 mg/dL) compared to the non-hemolysis group (179.5 mg/dL; 164–194 mg/dL). Multivariate logistic regression analysis revealed significant associations between hemolysis in Impella patients and TSAT (odds ratio [OR] = 0.03, 95% confidence interval [CI]: 0.00–0.18) and transferrin levels (OR = 19.6, 95% CI: 3.48–111). Conclusions The findings provide preliminary evidence of a potential link between iron metabolism and hemolysis in patients receiving Impella support. However, further exploration and validation through large-scale, prospective studies are required to establish the strength and consistency of this association.